Low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus idarubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia-Reference-Cited by-同舟云学术

Low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus idarubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia

Published:2014-11-03 Issue:6 Volume:56 Page:1691-1697
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Jin Jie,Chen Jian,Suo Shanshan,Qian Wenbin,Meng Haitao,Mai Wenyuan,Tong Hongyan,Huang Jian,Yu Wenjuan,Wei Juyin,Lou Yinjun

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.3109/10428194.2014.963074

Reference37 articles.

1. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry

2. Acute myeloid leukaemia

3. The Outcomes and Costs of Acute Myeloid Leukemia Among the Elderly

4. Survival for older patients with acute myeloid leukemia: a population-based study

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diversifying the anthracycline class of anti-cancer drugs identifies aclarubicin for superior survival of acute myeloid leukemia patients;Molecular Cancer;2024-06-04

2. Diverging the anthracycline class of anti-cancer drugs for superior survival of acute myeloid leukemia patients;2023-11-24

3. Efficacy and safety of decitabine combined with HAAG (homoharringtonine, aclarubicin, low-dose cytarabine and G-CSF) for newly diagnosed acute myeloid leukemia;Frontiers in Oncology;2022-10-12

4. Association of Platelet Count Detected by Novel Nano Probe with Prognosis After Initial Chemotherapy in Patients with Acute Myeloid Leukemia;Journal of Biomedical Nanotechnology;2022-10-01

5. Real-world treatment patterns and clinical outcomes in patients with AML in Japan who were ineligible for first-line intensive chemotherapy;International Journal of Hematology;2022-04-08